Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1983-04-18
1985-09-10
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514821, A61K 31415
Patent
active
045407070
ABSTRACT:
A method of inhibiting lipoxygenase in a patient, for the prophylaxis and/or treatment of ischaemias and disorders in cardiac rhythm and of rheumatic, allergic and asthmatic diseases, oedemas, pulmonary embolisms, pulmonary hypertension, oxygen intoxications and ulcerations which comprises administering to such patient an effective amount of nafazatrom.
REFERENCES:
patent: 4053621 (1977-10-01), Moller et al.
patent: 4372887 (1983-02-01), Wu et al.
R. Lucchesi et al., Overview, August M. Watanabe, 1984, Clinical Pharmacology of Antiarrhythmic Therapy, pp.73-76.
Busse Wolf-Dieter
Fiedler Volker
Hoffmeister Friedrich
Mardin Mithat
Mayer Dieter
Bayer Aktiengesellschaft
Waddell Frederick E.
LandOfFree
Nafazatrom as a lipoxygenase inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nafazatrom as a lipoxygenase inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nafazatrom as a lipoxygenase inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1428922